Liver Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Liver transplantation is the conventional therapy used in various liver diseases. The liver has the unique ability to regenerate or grow, unlike any other organ in the body. A liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. The immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

The liver transplant rejection pipeline market research report provides comprehensive information on the therapeutics under development for liver transplant rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for liver transplant rejection and features dormant and discontinued projects.

Key Targets in the Liver Transplant Rejection Pipeline Products Market

The key targets in the liver transplant rejection pipeline products market are Calcineurin, C-X-C Chemokine Receptor Type 1, C-X-C Chemokine Receptor Type 2, Cells Expressing B Lymphocyte Antigen CD20, Cells Expressing MHC Class I Antigen, and Complement C5.

Liver Transplant Rejection Pipeline Products Market Analysis by Targets

Liver Transplant Rejection Pipeline Products Market Analysis by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Liver Transplant Rejection Pipeline Products Market

The key mechanisms of action in the liver transplant rejection pipeline products market are Calcineurin Inhibitor, C-X-C Chemokine Receptor Type 1 Antagonist, C-X-C Chemokine Receptor Type 2 Antagonist, Complement C5 Inhibitor, Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20, and Cytotoxic To Cells Expressing MHC Class I Antigen.

Liver Transplant Rejection Pipeline Products Market Analysis by Mechanisms of Action

Liver Transplant Rejection Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Liver Transplant Rejection Pipeline Products Market

The key routes of administration in the liver transplant rejection pipeline products market are intravenous, parenteral, oral, inhalational, intraarterial, and intracerebral.

Liver Transplant Rejection Pipeline Products Market Analysis by Routes of Administration

Liver Transplant Rejection Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Liver Transplant Rejection Pipeline Products Market

The key molecule types in the liver transplant rejection pipeline products market are cell therapy, monoclonal antibody, small molecule, fusion protein, gene therapy, and gene-modified cell therapy.

Liver Transplant Rejection Pipeline Products Market Analysis by Molecule Types

Liver Transplant Rejection Pipeline Products Market Analysis by Molecule Types

For more molecule-type insights, download a free report sample

Key Companies in the Liver Transplant Rejection Pipeline Products Market

Some of the major companies in the liver transplant rejection pipeline products market are Junten Bio Co Ltd, Alexion Pharmaceuticals Inc, Astellas Pharma Inc, Dompe Farmaceutici SpA, Genexine Inc, and ITB-Med AB.

Liver Transplant Rejection Pipeline Products Market Analysis by Companies

Liver Transplant Rejection Pipeline Products Market Analysis by Companies

For more company insights, download a free report sample

Key Universities in the Liver Transplant Rejection Pipeline Products Market

Some of the key universities in the liver transplant rejection pipeline products market are King’s College London, Helmholtz Center Munich German Research Center for Health and Environment GmbH, Huazhong University of Science & Technology, Nanjing Medical University, and the University of Pittsburgh.

Liver Transplant Rejection Pipeline Products Market Analysis by Universities

Liver Transplant Rejection Pipeline Products Market Analysis by Universities

For more university insights, download a free report sample

Liver Transplant Rejection Pipeline Products Market Report Overview

Key Targets Calcineurin, C-X-C Chemokine Receptor Type 1, C-X-C Chemokine Receptor Type 2, Cells Expressing B Lymphocyte Antigen CD20, Cells Expressing MHC Class I Antigen, and Complement C5
Key Mechanisms of Action Calcineurin Inhibitor, C-X-C Chemokine Receptor Type 1 Antagonist, C-X-C Chemokine Receptor Type 2 Antagonist, Complement C5 Inhibitor, Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20, and Cytotoxic to Cells Expressing MHC Class I Antigen
Key Routes of Administration Intravenous, Parenteral, Oral, Inhalational, Intraarterial, and Intracerebral
Key Molecule Type Cell Therapy, Monoclonal Antibody, Small Molecule, Fusion Protein, Gene Therapy, and Gene-Modified Cell Therapy
Major Companies Junten Bio Co Ltd, Alexion Pharmaceuticals Inc, Astellas Pharma Inc, Dompe Farmaceutici SpA, Genexine Inc, and ITB-Med AB
Major Universities King’s College London, Helmholtz Center Munich German Research Center for Health and Environment GmbH, Huazhong University of Science & Technology, Nanjing Medical University, and University of Pittsburgh

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of liver transplant rejection (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for liver transplant rejection (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in liver transplant rejection (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates liver transplant rejection (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for liver transplant rejection (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for liver transplant rejection (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding liver transplant rejection (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Alexion Pharmaceuticals Inc
Astellas Pharma Inc
Dompe Farmaceutici SpA
Genexine Inc
ITB-Med AB
Junten Bio Co Ltd
Novartis AG
Pharmapraxis
Quell Therapeutics Ltd
Veloxis Pharmaceuticals AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Transplant Rejection – Overview

Liver Transplant Rejection – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Transplant Rejection – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Transplant Rejection – Companies Involved in Therapeutics Development

Alexion Pharmaceuticals Inc

Astellas Pharma Inc

Dompe Farmaceutici SpA

Genexine Inc

ITB-Med AB

Junten Bio Co Ltd

Novartis AG

Pharmapraxis

Quell Therapeutics Ltd

Veloxis Pharmaceuticals AS

Liver Transplant Rejection – Drug Profiles

Cellular Immunotherapy for Liver Transplant Rejection – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cellular Immunotherapy for Liver Transplantation – Drug Profile

Product Description

Mechanism Of Action

Cellular Immunotherapy for Liver Transplantation – Drug Profile

Product Description

Mechanism Of Action

eculizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy for High-Grade Glioma and Liver Transplantation – Drug Profile

Product Description

Mechanism Of Action

GXP-10 – Drug Profile

Product Description

Mechanism Of Action

iscalimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

JB-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

JB-102 – Drug Profile

Product Description

Mechanism Of Action

QEL-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

reparixin – Drug Profile

Product Description

Mechanism Of Action

History of Events

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

siplizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Liver Transplant Rejection and Kidney Transplant Rejection – Drug Profile

Product Description

Mechanism Of Action

tacrolimus – Drug Profile

Product Description

Mechanism Of Action

History of Events

tacrolimus ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

TR-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Liver Transplant Rejection – Dormant Projects

Liver Transplant Rejection – Discontinued Products

Liver Transplant Rejection – Product Development Milestones

Featured News & Press Releases

Jul 16, 2021: FDA approves new use of transplant drug based on real-world evidence

Jan 17, 2020: Astellas announces construction of new manufacturing facility for Active Pharmaceutical Ingredient of Prograf in Toyama Technology Center

Mar 18, 2019: Astellas launches PROGRAF Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

Dec 04, 2009: Hikma signs new agreement for Advagraf with Astellas

Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Liver Transplant Rejection, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Liver Transplant Rejection – Pipeline by Alexion Pharmaceuticals Inc, 2022

Liver Transplant Rejection – Pipeline by Astellas Pharma Inc, 2022

Liver Transplant Rejection – Pipeline by Dompe Farmaceutici SpA, 2022

Liver Transplant Rejection – Pipeline by Genexine Inc, 2022

Liver Transplant Rejection – Pipeline by ITB-Med AB, 2022

Liver Transplant Rejection – Pipeline by Junten Bio Co Ltd, 2022

Liver Transplant Rejection – Pipeline by Novartis AG, 2022

Liver Transplant Rejection – Pipeline by Pharmapraxis, 2022

Liver Transplant Rejection – Pipeline by Quell Therapeutics Ltd, 2022

Liver Transplant Rejection – Pipeline by Veloxis Pharmaceuticals AS, 2022

Liver Transplant Rejection – Dormant Projects, 2022

Liver Transplant Rejection – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Liver Transplant Rejection, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Liver Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Liver Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Liver Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.